S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS

ABSTRACT:

SUBMITTER: Garcia-Manero G 

PROVIDER: S-EPMC9642083 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature